Unraveling the molecular basis of ADC-related interstitial lung disease: from structural determinants to pathogenic pathways and mitigation strategies
Abstract
Despite being a revolutionary class of precision oncology therapeutics, antibody-drug conjugates (ADCs) face growing restrictions on clinical application due to one of their most significant and life-threatening side effects—interstitial lung disease (ILD). The incidence of ADC-related ILD (ADC-ILD) exhibits marked heterogeneity across agents (less than 1% to more than 15%), indicating that this toxicity is not a general class effect, but rather fundamentally linked to the molecular structure of individual ADC molecules. This review synthesizes the association of structural elements of ADCs (linker chemistry, properties of payload, drug-to-antibody ratio (DAR), and target selection) with the risk of ILD, based on clinical data and insights into the mechanism. We propose a multidimensional risk model, informed primarily by trastuzumab deruxtecan (T-DXd) mechanistic studies, wherein pulmonary toxicity may arise from the convergence of three structural liabilities: cleavable linkers, high DAR, and membrane-permeable payloads. From a mechanistic standpoint, evidence from preclinical models, particularly T-DXd-related studies, suggests that important events in ADC- ILD may involve target-independent processes, including Fcγ receptor-mediated sequestration of intact ADCs by alveolar macrophages, subsequent liberation of the payload into lysosomes, and bystander injury to alveolar epithelial cells; this cascade may trigger inflammatory amplification via the upregulation of secreted phosphoprotein 1 (SPP1) and contribute to fibrotic remodeling. This mechanistic paradigm supports a “safety-by-design” approach for the next-generation of ADC engineering, including Fc optimization, linker stabilization, payload permeability rationalization, and DAR optimization; this review establishes a conceptual basis for safer ADC development and better clinical risk stratification, framing ILD as a potentially predictable and structure-modulated toxicity, rather than an entirely idiosyncratic adverse event. It must be emphasized that the proposed FcγR–macrophage–SPP1 axis remains predominantly supported by murine and in vitro data, and its generalization across all ADC constructs and validation in human pulmonary tissue require further investigation.
Related
- Unraveling legionellosis dynamics in the Lazio Region: effects of individual, geographical and meteorological determinants
- Pathogenic transcriptional reprogramming of fibro-adipogenic progenitors in mice with FOP and its mitigation by inhibition of ACVR1 and activin A
- Unraveling the role of non-structural proteins in the life cycle of chikungunya virus
- Diagnostic ambiguity and in-hospital mortality determinants: a decadal analysis of interstitial lung disease hospitalization trends in Ecuador (2015-2024).
- Unraveling Gastrointestinal Symptoms in Hypermobile Ehlers–Danlos Syndrome: A Functional and Structural Diagnostic Perspective
BibTeX
@article{wang2026unraveling,
title = {{Unraveling the molecular basis of ADC-related interstitial lung disease: from structural determinants to pathogenic pathways and mitigation strategies}},
author = {Yige Wang and Qiang Xiao},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.1928286},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1928286},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Unraveling the molecular basis of ADC-related interstitial lung disease: from structural determinants to pathogenic pathways and mitigation strategies
AU - Yige Wang
AU - Qiang Xiao
PY - 2026
DA - 2026/11/03
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1928286
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1928286
AB - Despite being a revolutionary class of precision oncology therapeutics, antibody-drug conjugates (ADCs) face growing restrictions on clinical application due to one of their most significant and life-threatening side effects—interstitial lung disease (ILD). The incidence of ADC-related ILD (ADC-ILD) exhibits marked heterogeneity across agents (less than 1% to more than 15%), indicating that this toxicity is not a general class effect, but rather fundamentally linked to the molecular structure of individual ADC molecules. This review synthesizes the association of structural elements of ADCs (linker chemistry, properties of payload, drug-to-antibody ratio (DAR), and target selection) with the risk of ILD, based on clinical data and insights into the mechanism. We propose a multidimensional risk model, informed primarily by trastuzumab deruxtecan (T-DXd) mechanistic studies, wherein pulmonary toxicity may arise from the convergence of three structural liabilities: cleavable linkers, high DAR, and membrane-permeable payloads. From a mechanistic standpoint, evidence from preclinical models, particularly T-DXd-related studies, suggests that important events in ADC- ILD may involve target-independent processes, including Fcγ receptor-mediated sequestration of intact ADCs by alveolar macrophages, subsequent liberation of the payload into lysosomes, and bystander injury to alveolar epithelial cells; this cascade may trigger inflammatory amplification via the upregulation of secreted phosphoprotein 1 (SPP1) and contribute to fibrotic remodeling. This mechanistic paradigm supports a “safety-by-design” approach for the next-generation of ADC engineering, including Fc optimization, linker stabilization, payload permeability rationalization, and DAR optimization; this review establishes a conceptual basis for safer ADC development and better clinical risk stratification, framing ILD as a potentially predictable and structure-modulated toxicity, rather than an entirely idiosyncratic adverse event. It must be emphasized that the proposed FcγR–macrophage–SPP1 axis remains predominantly supported by murine and in vitro data, and its generalization across all ADC constructs and validation in human pulmonary tissue require further investigation.
SN - 1663-9812
ER -